Primary cancer-associated fibroblasts exhibit high heterogeneity among breast cancer subtypes.
breast cancer
cancer-associated fibroblasts
cells isolation
primary culture
tumour heterogeneity
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
12
2022
accepted:
02
05
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Cancer-associated fibroblasts (CAFs) are a diverse subset of cells, that is recently gaining in popularity and have the potential to become a new target for breast cancer (BC) therapy; however, broader research is required to understand their mechanisms and interactions with breast cancer cells. The goal of the study was to isolate CAFs from breast cancer tumour and characterise isolated cell lines. We concentrated on numerous CAF biomarkers that would enable their differentiation. Flow cytometry, immunofluorescence, and reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) were used to phenotype the primary CAFs. According to our findings, there was no significant pattern in the classification of cancer-associated fibroblasts. The results of biomarkers expression were heterogeneous, thus no specific subtypes were identified. Furthermore, a comparison of cancer-associated fibroblasts derived from different BC subtypes (luminal A and B, triple-negative, HER2 positive) did not reveal any clear trend of expression.
Sections du résumé
Background
UNASSIGNED
Cancer-associated fibroblasts (CAFs) are a diverse subset of cells, that is recently gaining in popularity and have the potential to become a new target for breast cancer (BC) therapy; however, broader research is required to understand their mechanisms and interactions with breast cancer cells. The goal of the study was to isolate CAFs from breast cancer tumour and characterise isolated cell lines. We concentrated on numerous CAF biomarkers that would enable their differentiation.
Materials and methods
UNASSIGNED
Flow cytometry, immunofluorescence, and reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) were used to phenotype the primary CAFs.
Results/Conclusions
UNASSIGNED
According to our findings, there was no significant pattern in the classification of cancer-associated fibroblasts. The results of biomarkers expression were heterogeneous, thus no specific subtypes were identified. Furthermore, a comparison of cancer-associated fibroblasts derived from different BC subtypes (luminal A and B, triple-negative, HER2 positive) did not reveal any clear trend of expression.
Identifiants
pubmed: 37456709
doi: 10.5603/RPOR.a2023.0026
pii: rpor-28-2-159
pmc: PMC10348329
doi:
Types de publication
Journal Article
Langues
eng
Pagination
159-171Informations de copyright
© 2023 Greater Poland Cancer Centre.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Biosci (Landmark Ed). 2020 Mar 1;25(5):961-978
pubmed: 32114420
J Cell Biol. 2017 Nov 6;216(11):3799-3816
pubmed: 29021221
Am J Cancer Res. 2022 Sep 15;12(9):4411-4427
pubmed: 36225645
EMBO Mol Med. 2010 Jun;2(6):211-30
pubmed: 20535745
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186-196
pubmed: 26278673
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Asian Pac J Cancer Prev. 2020 Dec 01;21(12):3587-3593
pubmed: 33369456
Front Oncol. 2018 Jun 14;8:227
pubmed: 29963498
Nat Commun. 2020 Jan 21;11(1):404
pubmed: 31964880
Breast Cancer Res. 2016 Mar 12;18(1):32
pubmed: 26968831
Front Cell Dev Biol. 2019 Apr 26;7:66
pubmed: 31080802
Front Cell Dev Biol. 2021 Jul 22;9:711381
pubmed: 34395440
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Sci. 2020 Aug;111(8):2708-2717
pubmed: 32573845
Oncol Rep. 2014 Mar;31(3):1127-32
pubmed: 24366074
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Exp Hematol Oncol. 2020 Dec 10;9(1):36
pubmed: 33303029
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Front Oncol. 2021 May 20;11:668731
pubmed: 34094963
Semin Cancer Biol. 2020 May;62:166-181
pubmed: 31415910
Cancer Gene Ther. 2021 Sep;28(9):984-999
pubmed: 33712707